Solvent effects on the structure-property relationship of anticonvulsant hydantoin derivatives: A solvatochromic analysis

Chemistry Central Journal

Volumn 5, Issue 1, 2011, Pages

  Trišović, Nemanja ^a   Valentić, Nataša ^a   Ušćumlić, Gordana ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80053940110     PISSN: None     EISSN: 1752153X     Source Type: Journal    
DOI: 10.1186/1752-153X-5-62     Document Type: Article

References (44)

1. Yaari Y, Selzer ME, Pincus JH: Phenytoin: mechanisms of its anticonvulsant action. Ann Neurol. 1986, 20: 171-184. 10.1002/ana.410200202.
2. Küpfer A, Brilis GM, Watson JT, Harris TM: A major pathway of mephenytoin metabolism in man. Aromatic hydroxylation to p-hydroxymephenytoin. Drug Metab Dispos. 1980, 8: 1-4.
3. Ellis FA: Reactions to nirvanol, phenytoin sodium and phenobarbital: report of a case of ectodermosis erosiva pluriorificialis following the ingestion of phenytoin sodium. South Med J. 1943, 36: 575-579. 10.1097/00007611-194308000-00007.
4. Carter CA, Helms RA, Boehm R: Ethotoin in seizures of childhood and adolescence. Neurol. 1984, 34: 791-795.
5. Brouillette WJ, Brown GB, DeLorey TM, Liang G: Sodium channel binding and anticonvulsant activities of hydantoins containing conformationally constrained 5-phenyl substituents. J Pharm Sci. 1990, 79: 871-874. 10.1002/jps.2600791005.
6. Brown ML, Brown GB, Brouillette WJ: Effects of log P and phenyl ring conformation on the binding of 5-phenylhydantoins to the voltage-dependent sodium channel. J Med Chem. 1997, 40: 602-607. 10.1021/jm960692v.
7. Smythies JR: Receptor modeling for anticonvulsant and convulsant drugs. Antiepileptic Drugs: Mechanism of Action. Edited by: Glasser GH, Penry JK, Woodbury DM. 1980, New York: Raven Press, 207-222.
8. Poupaert JH, Vandervorst D, Guiot P, Moustafa MMM, Dumont P: Structure-activity relationships of phenytoin-like anticonvulsant drugs. J Med Chem. 1984, 27: 76-78. 10.1021/jm00367a015.
9. Cortes S, Liao ZK, Watson D, Kohn H: Effect of structural modification of the hydantoin ring on anticonvulsant activity. J Med Chem. 1985, 28: 601-606. 10.1021/jm50001a012.
10. Roszak AW, Weaver DF: 5,5-Diphenyl-2-thiohydantoin. Acta Cryst C. 1998, 54: 1168-1170. 10.1107/S0108270197019963.
11. Scholl S, Koch A, Henning D, Kempter G, Kleinpeter E: The influence of structure and lipophilicity of hydantoin derivatives on anticonvulsant activity. Struct Chem. 1999, 10: 355-366. 10.1023/A:1022091411018.
12. Abraham MH, Lieb WR, Franks NP: Role of hydrogen bonding in general anesthesia. J Pharm Sci. 1991, 80: 719-724. 10.1002/jps.2600800802.
13. Abraham MH: Application of solvation equations to chemical and biochemical processes. Pure Appl Chem. 1993, 65: 2503-2512. 10.1351/pac199365122503.
14. Abraham MH, Ibrahim A, Zissimos AM, Zhao YH, Comer J, Reynolds DP: Application of hydrogen bonding calculations in property based drug design. Drug Discov Today. 2002, 7: 1056-1063. 10.1016/S1359-6446(02)02478-9.
15. Perišić-Janjić N, Kaliszan R, Wiczling P, Milošević N, Ušćumlić G, Banjac N: Reversed-phase TLC and HPLC retention data in correlation studies with in silico molecular descriptors and druglikeness droperties of newly synthesized anticonvulsant succinimide derivatives. Mol Pharmaceut. 2011, 8: 555-563. 10.1021/mp100373d.
16. Kamlet MJ, Abboud JLM, Abraham MH, Taft RW: Linear solvation energy relationships. 23. A comprehensive collection of the solvatochromic parameters, Π, α, and β, and some methods for simplifying the generalized solvatochromic equation. J Org Chem. 1983, 48: 2877-2887. 10.1021/jo00165a018.
17. Banjac N, Ušćumlić G, Valentić N, Mijin D: Solvent effects on the structure-activity relationship of pharmacological active 3-substituted-5,5-diphenylhydantoins. J Solution Chem. 2007, 36: 869-878. 10.1007/s10953-007-9153-2.
18. Trišović N, Banjac N, Valentić N, Ušćumlić G: Solvent effects on the structure-activity relationship of phenytoin-like anticonvulsant drugs. J Solution Chem. 2009, 38: 199-208. 10.1007/s10953-008-9367-y.
19. Bucherer HT, Lieb VA: Syntheses of hydantoins. II. Formation of substituted hydantoins from aldehydes and ketones. J Prakt Chem. 1934, 141: 5-43. 10.1002/prac.19341410102.
20. Suzuki H, Kneller MB, Rock DA, Jones JP, Trager WF, Rettie AE: Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors. Arch Biochem Biophys. 2004, 429: 1-15. 10.1016/j.abb.2004.05.015.
21. Muccioli GG, Poupaert JH, Wouters J, Norberg B, Poppitz W, Scriba GKE, Lambert DM: A rapid and efficient microwave-assisted synthesis of hydantoins and thiohydantoins. Tetrahedron. 2003, 59: 1301-1307. 10.1016/S0040-4020(03)00033-4.
22. Trišović N, Valentić N, Erović M, Daković-Sekulić T, Ušćumlić G, Juranić I: Synthesis, structure and solvatochromic properties of pharmacologically active 5-substituted 5-phenylhydantoins. Monats Chem. 10.1007/s00706-011-0639-7. doi:10.1007/s00706-011-0639-7.
23. Marcus Y: The properties of organic liquids that are relevant to their use as solvating solvents. Chem Soc Rev. 1993, 22: 409-416. 10.1039/cs9932200409.
24. Mather D, Shorter J: The influence of the solvent on organic reactivity. Part 5. Kinetics of the reaction of diazodiphenylmethane with benzoic acid in branched-chain alkanols and in electronegatively substituted alcohols. J Chem Soc Perkin Trans II. 1983, 1179-1183.
25. Bauer M, Rollberg A, Barth A, Spange S: Differentiating between dipolarity and polarizability effects of solvents using the solvatochromism of barbiturate dyes. Eur J Org Chem. 2008, 4475-4481.
26. Stuckey RE: The absorption spectra of organic compounds containing nitrogen. I. Derivatives of hydantoin. J Chem Soc. 1947, 169: 331-334.
27. Tan SF, Ang KP, Fong YF, Jayachandran H: Ionization constants of 5-arylmethylenehydantoins in 80% (w/w) dimethyl sulfoxide-water at 25°. J Chem Soc Perkin Trans II. 1988, 473-476.
28. Reinchard C: Solvents and Solvent Effects in Organic Chemistry. 2003, Weinheim: Wiley - VCH, 457.
29. Unger SH, Hansch C: Quantitative models of steric effects. Prog Phys Org Chem. 1976, 12: 91-118.
30. Komiya I, Park JY, Kamani A, Ho NFH, Higuchi WI: Quantitative mechanistic studies in simultaneous fluid flow and intestinal absorption using steroids as model solutes. Int J Pharm. 1980, 4: 249-262. 10.1016/0378-5173(80)90140-4.
31. Taylor DC, Pownwall R, Burke W: The absorption of β-adrenoceptor antagonists in rat in-situ small intestine the effect of lipophilicity. J Pharm Pharmacol. 1985, 37: 280-283.
32. Levin VA: Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem. 1980, 23: 682-684. 10.1021/jm00180a022.
33. Artursson P: Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J Pharm Sci. 1990, 79: 476-482. 10.1002/jps.2600790604.
34. Buur A, Trier L, Magnusson C, Artursson P: Permeability of 5-fluorouracil and prodrugs in Caco-2 cell monolayers. Int J Pharm. 1996, 129: 223-231. 10.1016/0378-5173(95)04331-4.
35. Zhao YH, Le J, Abraham MH, Hersey A, Eddershaw PJ, Luscombe CN, Boutina D, Beck G, Sherborne B, Cooper I, Platts JA: Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. J Pharm Sci. 2001, 90: 749-784. 10.1002/jps.1031.
36. Zhao YH, Abraham MH, Hersey A, Luscombe CN: Quantitative relationship between rat intestinal absorption and Abraham descriptors. Eur J Med Chem. 2003, 38: 939-947. 10.1016/j.ejmech.2003.07.005.
37. Hansch C, Björkroth JP, Leo A: Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. J Pharm Sci. 1987, 76: 663-687. 10.1002/jps.2600760902.
38. Yamagami C, Sonoda C, Takao N, Tanaka M, Yamada J, Horisaka K, Fujita T: A quantitative structure-activity study of anticonvulsant benzyl N,N-dimethylcarbamates. Chem Pharm Bull. 1982, 30: 4175-4180.
39. Lombardo F, Blake JF, Curatolo WJ: Computation of brain-blood partitioning of organic solutes via free energy calculations. J Med Chem. 1996, 39: 4750-4755. 10.1021/jm960163r.
40. Hou T, Xu X: ADME evaluation in drug discovery. 1. Applications of genetic algorithms to the prediction of blood-brain partitioning of a large set of drugs. J Mol Model. 2002, 8: 337-349.
41. Norinder U, Haeberlein M: Computational approaches to the prediction of the blood-brain distribution. Adv Drug Deliv Rev. 2002, 54: 291-313. 10.1016/S0169-409X(02)00005-4.
42. Peterson GM, McLean S, Aldous S, von Witt RJ, Mollingen KS: Plasma protein binding of phenytoin in 100 epileptic patients. Brit J Clin Pharmacol. 1982, 14: 298-300.
43. Seedher N, Agarwal P: Reversible binding of some isoxazolyl penicillins with serum albumin using fluorescence spectroscopic technique. Ind J Pharm Sci. 2006, 68: 327-331. 10.4103/0250-474X.26667.
44. Kratochwil NA, Huber W, Müller F, Kansy M, Gerber PR: Predicting plasma protein binding of drugs: a new approach. Biochem Pharmacol. 2002, 64: 1355-1374. 10.1016/S0006-2952(02)01074-2.